<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070119</url>
  </required_header>
  <id_info>
    <org_study_id>233AS102</org_study_id>
    <secondary_id>2016-003225-41</secondary_id>
    <nct_id>NCT03070119</nct_id>
  </id_info>
  <brief_title>Long-Term Evaluation of BIIB067</brief_title>
  <official_title>An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the long-term safety and tolerability of
      BIIB067 in participants with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1
      Mutation (SOD1-ALS). The secondary objective is to evaluate the pharmacokinetic (PK) profile
      of BIIB067 in participants with SOD1-ALS.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing AEs and serious adverse events (SAEs)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Safety Surveillance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory assessment abnormalities</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Safety Surveillance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Safety Surveillance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Safety Surveillance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Safety Surveillance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Safety Surveillance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in cerebrospinal fluid (CSF): Cmax</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Time to reach the maximum observed concentration (Tmax)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in CSF: Tmax</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Area under the concentration-time curve from time 0 to infinity (AUCinf)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in CSF: AUCinf</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Area under the concentration-time curve from time 0 to time of the last measurable (AUClast)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in CSF: AUClast</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Apparent terminal elimination half-life (t½)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB067 in CSF: t½</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Venipuncture for PK data collection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation</condition>
  <arm_group>
    <arm_group_label>BIIB067 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB067 Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB067 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB067</intervention_name>
    <description>Participants will receive a loading dose regimen followed by maintenance dosing.</description>
    <arm_group_label>BIIB067 Low dose</arm_group_label>
    <arm_group_label>BIIB067 Mid dose</arm_group_label>
    <arm_group_label>BIIB067 High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have diagnosis of SOD1-ALS, and must have completed Part A and/or Part B of Study
             233AS101 (NCT02623699) (i.e., were not withdrawn and did not miss more than 1 dose of
             study drug).

          -  If taking riluzole, must be receiving a stable dose for ≥30 days prior to Day 1 and
             expected to remain at that dose until the final study visit.

          -  For participants of childbearing potential must agree to practice effective
             contraception during the study and for 5 months after their last dose of study
             treatment.

          -  Medically able to undergo the study procedures, and to adhere to the visit schedule at
             the time of study entry, as determined by the Investigator.

        Key Exclusion Criteria:

          -  History of or positive test result for human immunodeficiency virus.

          -  History of or positive test result for hepatitis C virus antibody or hepatitis B virus
             (defined as positive for both hepatitis B surface antigen and hepatitis B core
             antibody).

          -  History of allergies to a broad range of anesthetics.

          -  Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that
             is not managed optimally and could place a participant at an increased risk for
             bleeding during or after a Lumbar Puncture (LP) procedure. These risks could include,
             but are not limited to, anatomical factors at or near the LP site (e.g., vascular
             abnormalities, neoplasms, or other abnormalities) and underlying disorders of the
             coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von
             Willebrand's disease, liver disease).

          -  Presence of an implanted shunt for the drainage of CSF or an implanted central nervous
             system (CNS) catheter.

          -  Prior or current treatment with small interfering ribonucleic acid (RNA), stem cell
             therapy, or gene therapy.

          -  Treatment with another investigational drug, biological agent (excluding BIIB067), or
             device within 1 month or 5 half-lives of study agent, whichever is longer.

          -  Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing
             system (DPS) during the study period.

          -  Female participants who are pregnant or currently breastfeeding.

          -  Current enrollment in any other interventional study.

          -  Current or recent (within 1 month) use, or anticipated need, in the opinion of the
             Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or
             pyrimethamine.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0949</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S102HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Superoxide Dismutase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

